Shares of Dova Pharmaceuticals Inc (NASDAQ:DOVA) have received a consensus recommendation of “Hold” from the eight research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $36.00.
Several equities analysts have issued reports on DOVA shares. Zacks Investment Research upgraded shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 target price on the stock in a research note on Wednesday, October 10th. BidaskClub upgraded shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, October 13th. Leerink Swann lowered their price objective on shares of Dova Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating on the stock in a research note on Tuesday, September 4th. Finally, Raymond James assumed coverage on shares of Dova Pharmaceuticals in a research note on Wednesday, August 29th. They issued an “outperform” rating and a $44.00 price objective on the stock.
Several large investors have recently modified their holdings of DOVA. BlackRock Inc. lifted its stake in shares of Dova Pharmaceuticals by 76.5% in the 2nd quarter. BlackRock Inc. now owns 1,144,920 shares of the company’s stock worth $34,257,000 after purchasing an additional 496,306 shares during the period. Nexthera Capital LP raised its stake in Dova Pharmaceuticals by 44.4% during the 2nd quarter. Nexthera Capital LP now owns 820,348 shares of the company’s stock worth $24,545,000 after acquiring an additional 252,105 shares during the period. Sphera Funds Management LTD. bought a new stake in Dova Pharmaceuticals during the 3rd quarter worth approximately $2,516,000. Candriam Luxembourg S.C.A. raised its stake in Dova Pharmaceuticals by 95.6% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 233,200 shares of the company’s stock worth $4,890,000 after acquiring an additional 114,000 shares during the period. Finally, Northern Trust Corp raised its stake in Dova Pharmaceuticals by 154.2% during the 2nd quarter. Northern Trust Corp now owns 163,116 shares of the company’s stock worth $4,881,000 after acquiring an additional 98,955 shares during the period. Hedge funds and other institutional investors own 37.14% of the company’s stock.
DOVA traded down $0.37 during midday trading on Wednesday, hitting $14.71. 159,810 shares of the company traded hands, compared to its average volume of 191,247. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.40 and a current ratio of 7.50. The stock has a market capitalization of $420.24 million, a P/E ratio of -10.51 and a beta of 0.71. Dova Pharmaceuticals has a 52 week low of $14.09 and a 52 week high of $37.00.
Dova Pharmaceuticals (NASDAQ:DOVA) last posted its earnings results on Thursday, November 8th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.12. The company had revenue of $2.93 million for the quarter, compared to the consensus estimate of $2.66 million. Research analysts forecast that Dova Pharmaceuticals will post -2.63 EPS for the current fiscal year.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
See Also: Why is the conference call important?